Imugene Dirección

Dirección controles de criterios 1/4

El CEO de Imugene es Leslie Chong , nombrado en Nov 2016, tiene una permanencia de 6.67 años. compensación anual total es A$2.50M, compuesta por 31.2% salario y 68.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.07% de las acciones de la empresa, por valor de A$2.96M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 6.1 años, respectivamente.

Información clave

Leslie Chong

Chief Executive Officer (CEO)

AU$2.5m

Compensación total

Porcentaje del salario del CEO	31.2%
Permanencia del CEO	8yrs
Participación del CEO	1.1%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Leslie Chong en comparación con los beneficios de Imugene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$2m	AU$780k	-AU$150m
Mar 31 2024	n/a	n/a	-AU$119m
Dec 31 2023	n/a	n/a	-AU$89m
Sep 30 2023	n/a	n/a	-AU$64m
Jun 30 2023	AU$2m	AU$750k	-AU$38m
Mar 31 2023	n/a	n/a	-AU$39m
Dec 31 2022	n/a	n/a	-AU$40m
Sep 30 2022	n/a	n/a	-AU$39m
Jun 30 2022	AU$1m	AU$600k	-AU$38m
Mar 31 2022	n/a	n/a	-AU$33m
Dec 31 2021	n/a	n/a	-AU$27m
Sep 30 2021	n/a	n/a	-AU$23m
Jun 30 2021	AU$789k	AU$408k	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$11m
Jun 30 2020	AU$733k	AU$375k	-AU$11m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$9m
Sep 30 2019	n/a	n/a	-AU$8m
Jun 30 2019	AU$777k	AU$350k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$7m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$403k	AU$300k	-AU$4m

Compensación vs. Mercado: La compensación total de Leslie($USD1.63M) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD688.70K).

Compensación vs. Ingresos: La compensación de Leslie ha aumentado mientras la empresa no es rentable.

CEO

Leslie Chong

8yrs

Permanencia

AU$2,497,743

Compensación

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hopper	Executive Chairman	12.1yrs	AU$491.35k	5.5% A$ 16.4m
Leslie Chong	CEO, MD & Executive Director	8yrs	AU$2.50m	1.07% A$ 3.2m
Michael Tonroe	CFO & Company Secretary	2.2yrs	AU$810.31k	sin datos
Bradley Glover	Chief Operating Officer	1.3yrs	AU$1.75m	sin datos
Joseph Woodard	Chief Medical Officer	1.2yrs	AU$1.39m	sin datos
Ursula McCurry	Chief Clinical Operations Officer	2.8yrs	sin datos	sin datos
John Byon	Senior Vice President of Clinical Development	1.2yrs	sin datos	sin datos

1.7yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMU no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hopper	Executive Chairman	12.1yrs	AU$491.35k	5.5% A$ 16.4m
Leslie Chong	CEO, MD & Executive Director	6.7yrs	AU$2.50m	1.07% A$ 3.2m
Kimberlee Drapkin	Non-Executive Director	1.4yrs	AU$92.40k	0.0016% A$ 4.8k
Yuman Fong	Chair of Oncolytic Virotherapy Scientific Advisory Board	5yrs	sin datos	0.30% A$ 895.1k
Neil Segal	Member of Scientific Advisory Board	10.6yrs	sin datos	sin datos
Josep Tabernero Caturla	Member of Scientific Advisory Board	6.1yrs	sin datos	sin datos
Yelena Janjigian	Scientific Advisory Board Member	8.6yrs	sin datos	sin datos
Lesley Russell	Independent Non-Executive Director	5.6yrs	AU$114.50k	0.27% A$ 809.5k
Peter Schmid	Member of Scientific Advisory Board	6.9yrs	sin datos	sin datos
Tanios Bekaii-Saab	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Pravin T. Kaumaya	Member of Scientific Advisory Board	6.1yrs	sin datos	sin datos

6.2yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de IMU se considera experimentada (6.1 años de antigüedad promedio).

Imugene Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Imugene Limited Announces Retirement of Jens Eckstein as Non-Executive Director

Imugene Limited, Annual General Meeting, Nov 14, 2024

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Recent updates

No longer forecast to breakeven

Imugene Limited Announces Retirement of Jens Eckstein as Non-Executive Director

Price target decreased by 17% to AU$0.29

Imugene Limited, Annual General Meeting, Nov 14, 2024

Imugene Limited Announces Promising Results from its Phase 1b Clinical Trial with Azer-Cel

New minor risk - Financial position

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Forecast to breakeven in 2027

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock